Canada markets closed

Curative Biotechnology, Inc. (CUBT)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.02000.0000 (0.00%)
At close: 12:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.0200
Open0.0200
BidN/A x N/A
AskN/A x N/A
Day's Range0.0152 - 0.0200
52 Week Range0.0101 - 0.0830
Volume346,874
Avg. Volume620,889
Market Cap10.758M
Beta (5Y Monthly)272.39
PE Ratio (TTM)
EPS (TTM)0.0000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Curative Biotechnology Announces Intent to Uplist to NYSE American Exchange

    Boca Raton, FL, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that it intends to offer shares of its common stock for sale in an underwritten public offering, after giving effect to the Company’s proposed 1-for-400 reverse stock split. In addition, the Company expects to grant the underwriter a 45-day option to pu

  • GlobeNewswire

    Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of Directors

    Appointment of Independent Director Builds Upon Biotech Expertise Boca Raton, FL, June 16, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that Lawrence S. Zaslow has joined its Board of Directors as an independent director and will chair its Compensation Committee. Mr. Zaslow co-founded BioTheryX, Inc. (https://biotheryx.com

  • GlobeNewswire

    Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of Directors

    Appointment of Independent Director Adds to Financial Expertise on Board Boca Raton, FL, May 12, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that Cary Sucoff has joined its Board of Directors as an independent director. With over 35 years of legal and securities industry experience, Cary Sucoff has participated in the fin